Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

CIN: L24230GJ1993PLC019050

www.sunpharma.com



FOR IMMEDIATE RELEASE

Sun Pharma to hold an Investor Update Call on December 03, 2018

December 03, 2018, Mumbai: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) will hold an Investor Update call on December 03, 2018.

Investor update call (06.30 pm IST, December 03, 2018)

The Company will conduct a call at 06.30 pm IST on December 03, 2018 where senior management will update Investors. To participate in this conference call, please dial the numbers provided below, five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

Event	Date and time	Telephone number/ website
Investor Update Call press release	December 03, 2018	www.sunpharma.com
Investor Update Conference Call	06.30 pm IST, December, 03, 2018	Primary Number: +91 22 6280 1278 +91 22 7115 8179 Via audio webcast, details of which will be made available on www.sunpharma.com
Replay of conference call	December 03, 2018 to December 10, 2018	URL: https://ccreservations.com/recordings/select_recordings.php Recording Id: SUN032018120376858 Via audio webcast playback, details of which will be made available on www.sunpharma.com

Registered Office: SPARC, Tandalja, Vadodara – 390 012. India

Sun Pharmaceutical Industries Ltd. SUN HOUSE, CTS No. 201 B/1. Western Express Highway. Goregaon (E).

Mumbai 400063. India

Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343

CIN: L24230GJ1993PLC019050

www.sunpharma.com



Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world. Sun Pharma's global presence is supported by 42 manufacturing facilities spread across 6 continents, R&D centres across the globe and a multi-cultural workforce comprising over 50 nationalities. In India, the company enjoys leadership across 12 different classes of doctors with 27 brands featuring amongst top 300 pharmaceutical brands in India. Its footprint across emerging markets covers over 100 markets and 6 markets in Western Europe. Its Global Consumer Healthcare business is ranked amongst Top 10 across 3 global markets. Its API business footprint is strengthened through 14 world class API manufacturing facilities across the globe. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and R&D investments of approximately 8% of annual revenues. For further information, please visit www.sunpharma.com & follow us on Twitter @SunPharma Live.

Contacts

Tel

Nimish Desai

+91 22 4324 4324, Xtn 2778

Tel Direct +91 22 4324 2778 +91-98203 30182 Mobile

nimish.desai@sunpharma.com E mail

Gaurav Chugh

Tel +91 22 4324 4324, Xtn 5373

Tel Direct +91 22 4324 5373 Mobile +91 98104 71414

E mail Gaurav.chugh@sunpharma.com